|
1.
|
|
11 p, 2.1 MB |
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
/
Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Codony-Servat, Jordi (Institut Universitari Dexeus) ;
Giménez-Capitán, Ana (Institut Universitari Dexeus) ;
Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Llige, David (Institut Germans Trias i Pujol) ;
Chaib, Imane (Institut Germans Trias i Pujol) ;
Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Karachaliou, Niki (Institut Universitari Dexeus) ;
Molina-Vila, Miguel Angel (Institut Universitari Dexeus) ;
Okada, Morihito (Hiroshima University. Department of Surgical Oncology) ;
Rosell, Rafael (Institut Germans Trias i Pujol)
EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. [...]
2020 -  10.1016/j.jtocrr.2020.100084
JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020)
|
|
|
2.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixido, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona Zorrilla, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (Centro de Investigación Biomédica en Red de Cáncer) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Angel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
3.
|
|
6 p, 538.4 KB |
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
/
Bonanno, Laura (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ;
Costa, Carla (Pangaea Biotech (Barcelona, Catalunya)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Sanchez, Jose-Javier (Universidad Autónoma de Madrid) ;
Rodriguez, Ignacio (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ;
Molina-Vila, Miquel Angel (Pangaea Biotech (Barcelona, Catalunya)) ;
Vergnenegre, Alain (Hospital du Cluzeau, 23, rue Larey, Limoges, France) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Favaretto, Adolfo (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ;
Rugge, Massimo (Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy) ;
Pallares, Cinta (Institut d'Investigació Biomèdica Sant Pau) ;
Taron, Miquel (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Universitat Autònoma de Barcelona
BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. [...]
2016 - 10.1186/s12885-016-2339-5
BMC Cancer, Vol. 16 (may 2016)
|
|
|
4.
|
|
7 p, 627.6 KB |
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer
/
Wei, J. (Clinical Cancer Institute of Nanjing University) ;
Costa, C. (Institut Dexeus) ;
Shen, J. (Clinical Cancer Institute of Nanjing University) ;
Yu, L. (TClinical Cancer Institute of Nanjing University) ;
Sanchez, J. J. (Universidad Autónoma de Madrid. Departamento de Medicina Preventiva y Salud Pública) ;
Qian, X (Clinical Cancer Institute of Nanjing University) ;
Sun, X (Clinical Cancer Institute of Nanjing University) ;
Zou, Z. (Clinical Cancer Institute of Nanjing University) ;
Giménez-Capitán, Ana (Institut Dexeus) ;
Yue, G. (Clinical Cancer Institute of Nanjing University) ;
Guan, W. (Nanjing University. Department of General Surgery) ;
Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Liu, B. (Clinical Cancer Institute of Nanjing University) ;
Universitat Autònoma de Barcelona
Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET domain (MMSET) and ubiquitin-conjugating enzyme 9 (UBC9) are involved in DNA repair and could modify the BRCA1 predictive model. [...]
2014 - 10.1038/bjc.2014.231
British Journal of Cancer, Vol. 110 (05 2014) , p. 2662-2668
|
|
|
5.
|
|
9 p, 287.7 KB |
The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
/
Margeli, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tapia, Gustavo (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Costa, Carla (Institut Universitari Dexeus) ;
Giménez-Capitán, Ana (Institut Universitari Dexeus) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Ronco, Maria Sanchez (Universidad de Alcalá) ;
Benlloch, Susana (Institut Universitari Dexeus) ;
Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. [...]
2010 - 10.1371/journal.pone.0009499
PloS one, Vol. 5 (3 2010)
|
|
|
6.
|
|
12 p, 942.4 KB |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
/
Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ;
Pilotto, Sara (University of Verona (Itàlia)) ;
Drozdowskyj, Ana (Pivotal (Madrid)) ;
Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ;
Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ;
Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ;
Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Gervais, Radj (Centre François Baclesse (Caen, França)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ;
Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ;
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ;
De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ;
Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ;
Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ;
Bria, Emilio (University of Verona (Itàlia)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
